

# Yang Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6314773/publications.pdf>

Version: 2024-02-01

29  
papers

1,854  
citations

430754

18  
h-index

454834

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3116  
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivery of nVEGF <sub>i</sub> using AAV8 for the treatment of neovascular age-related macular degeneration. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 210-221.	1.8	5
2	A universal strategy for AAV delivery of base editors to correct genetic point mutations in neonatal PKU mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 230-240.	1.8	13
3	Carrier strategies boost the application of CRISPR/Cas system in gene therapy. <i>Exploration</i> , 2022, 2, .	5.4	30
4	Liver-directed gene therapy corrects neurologic disease in a murine model of mucopolysaccharidosis type I-Hurler. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 370-381.	1.8	3
5	Eliminating predictable DNA off-target effects of cytosine base editor by using dual guiders including sgRNA and TALE. <i>Molecular Therapy</i> , 2022, 30, 2443-2451.	3.7	7
6	BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. <i>Oncogene</i> , 2021, 40, 1516-1530.	2.6	14
7	InÂvivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 652-659.	1.8	26
8	SARI suppresses colitis-associated cancer development by maintaining MCPâ€mediated tumour-associated macrophage recruitment. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 189-201.	1.6	4
9	A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 20-29.	2.0	20
10	CRISPR-Cas9-Mediated InÂvivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 520-531.	1.8	34
11	sgBE: a structure-guided design of sgRNA architecture specifies base editing window and enables simultaneous conversion of cytosine and adenosine. <i>Genome Biology</i> , 2020, 21, 222.	3.8	15
12	A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. <i>Science Advances</i> , 2020, 6, eaax5701.	4.7	44
13	Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 689-698.	1.9	35
14	SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells. <i>Mucosal Immunology</i> , 2019, 12, 1130-1140.	2.7	13
15	CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. <i>Blood</i> , 2019, 133, 2745-2752.	0.6	57
16	Targeted demethylation of the SARI promotor impairs colon tumour growth. <i>Cancer Letters</i> , 2019, 448, 132-143.	3.2	31
17	Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. <i>Molecular Therapy</i> , 2019, 27, 244-260.	3.7	67
18	Progress in the treatment of infantile hemangioma. <i>Annals of Translational Medicine</i> , 2019, 7, 692-692.	0.7	38

#	ARTICLE	IF	CITATIONS
19	Recent Advances in Therapeutic Genome Editing in China. <i>Human Gene Therapy</i> , 2018, 29, 136-145.	1.4	5
20	Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. <i>Science China Life Sciences</i> , 2017, 60, 458-467.	2.3	40
21	CRISPR/Cas9-mediated correction of human genetic disease. <i>Science China Life Sciences</i> , 2017, 60, 447-457.	2.3	34
22	A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. <i>Nature Biotechnology</i> , 2016, 34, 334-338.	9.4	476
23	Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. <i>Molecular Therapy</i> , 2013, 21, 358-367.	3.7	164
24	Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Cancer. <i>Molecular Pharmaceutics</i> , 2012, 9, 2280-2289.	2.3	79
25	Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. <i>Molecular Therapy</i> , 2012, 20, 609-615.	3.7	116
26	IL15 combined with Casp2 provides enhanced therapeutic efficiency against murine malignant neoplasm growth and metastasis. <i>Cancer Gene Therapy</i> , 2012, 19, 460-467.	2.2	4
27	Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. <i>Journal of Controlled Release</i> , 2012, 158, 108-114.	4.8	279
28	SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 4439-4450.	3.2	92
29	Efficient Inhibition of Non-Small-Cell Lung Cancer Xenograft by Systemic Delivery of Plasmid-Encoding Short-Hairpin RNA Targeting VEGF. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2010, 25, 65-73.	0.7	18